AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE

AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE

According to the World Health Organization, anxiety and depressive disorders will be the second leading cause of disability by 2020. The review is devoted to the modern concepts of the pathophysiology of depression in patients with ischemic heart disease (IHD) and to the possibilities of antidepre...

Full description

Bibliographic Details
Main Authors:	N. Yu. Shimohina, M. M. Petrova, A. A. Savchenko, M. S. Chernyaeva
Format:	Article
Language:	English
Published:	Столичная издательская компания 2017-03-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	anxiety depression ischemic heart disease antidepressants agomelatine
Online Access:	https://www.rpcardio.online/jour/article/view/1425

Similar Items

Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine
by: D. S. Petelin, et al.
Published: (2021-12-01)

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine
by: Dan J. Stein
Published: (2023-04-01)

Adherence to antidepressant therapy: clinical experience on the example of agomelatine
by: N. N. Petrova
Published: (2022-08-01)

Agomelatine – pharmacological properties and use in psychiatric practice
by: Marcin Siwek, et al.
Published: (2019-06-01)

Suspected Agomelatine-induced restless legs syndrome: a case report
by: Mustafa Abdul Karim, et al.
Published: (2021-04-01)

Comparing the effect of agomelatine and sertraline in treating patients with major depression disorder
by: Afshin Ahmadvand, et al.
Published: (2023-09-01)

Impact of different classes of antidepressants on sleep and wakefulness regulation in depression
by: G. M. Usov, et al.
Published: (2022-02-01)

Sub-Acute Oral Toxicity of a Novel Derivative of Agomelatine in Rats in a Sex-Dependent Manner
by: Qiushi Yang, et al.
Published: (2019-03-01)

Approaches to therapy for depressions in neurology: prospects for the use of agomelatine
by: D. V. Romanov, et al.
Published: (2018-12-01)

Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
by: Medvedev VE
Published: (2017-04-01)

Efficacy and safety of agomelatine and SSRIs in the treatment of depressive disorder： a network Meta-analysis
by: Guo Huihui, et al.
Published: (2022-06-01)

Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial
by: Che T, et al.
Published: (2018-06-01)

Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease
by: Qiang Su, et al.
Published: (2023-01-01)

Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
by: Shek Ming Leung
Published: (2021-08-01)

Agomelatine in the treatment of anhedonia, somatic symptoms, and sexual dysfunction in major depressive disorder
by: Juan Huang, et al.
Published: (2023-04-01)

Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression
by: L. I. Abramova, et al.
Published: (2019-06-01)

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
by: Chen JW, et al.
Published: (2018-02-01)

Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model
by: Ahmet Yardimci, et al.
Published: (2021-06-01)

Alopecia associated with agomelatine use: a case report
by: Ibrahim Gundogmus, et al.
Published: (2018-01-01)

DEPRESSION IN NEUROLOGICAL PRACTICE
by: D. V. Romanov, et al.
Published: (2018-02-01)

DRUG REPOSITIONING: Revisiting the basic psychopharmacological mechanism of action for agomelatine and where it should be classified?
by: Olumuyiwa John Fasipe, et al.
Published: (2019-01-01)

Comparison of the effects of sertraline and agomelatine on sleep quality, sexual functioning and metabolic parameters in patients with major depressive disorder
by: Anıl Talas, et al.
Published: (2019-07-01)

Parallel Changes in Mood and Melatonin Rhythm Following an Adjunctive Multimodal Chronobiological Intervention With Agomelatine in People With Depression: A Proof of Concept Open Label Study
by: Rebecca Robillard, et al.
Published: (2018-12-01)

Acute angle closure glaucoma induced by selective serotonin reuptake inhibitor, and reversed by agomelatine
by: Mehmet Emin Demirkol, et al.
Published: (2019-12-01)

Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm
by: Liliana Civalleri, et al.
Published: (2012-09-01)

UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE DETERMINATION OF AGOMELATINE IN COATED TABLETS
by: Fábio de Souza Barbosa, et al.
Published: (2017-12-01)

Novel Conformationally Constrained Analogues of Agomelatine as New Melatoninergic Ligands
by: Marouan Rami, et al.
Published: (2012-12-01)

Agomelatine's antiglycoxidative action—In vitro and in silico research and systematic literature review
by: Miłosz Nesterowicz, et al.
Published: (2023-04-01)

Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling
by: Jana Tchekalarova, et al.
Published: (2018-07-01)

Compliance among patients with depressive and anxiety disorders
by: Aleksandra Gorostowicz, et al.
Published: (2019-06-01)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
by: Zhe Li, et al.
Published: (2023-06-01)

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects
by: Fang Tang, et al.
Published: (2016-01-01)

Modern strategies for the treatment of psychoemotional stress in patients with heart coronary disease after myocardial revascularization
by: B. M. Holdovskyy, et al.
Published: (2019-04-01)

Agomelatine Changed the Expression and Methylation Status of Inflammatory Genes in Blood and Brain Structures of Male Wistar Rats after Chronic Mild Stress Procedure
by: Katarzyna Bialek, et al.
Published: (2022-08-01)

The effects of agomelatine in cisplatin-induced toxicity on the kidney and liver tissues: In vivo study
by: Fatma Nihan Cankara, et al.
Published: (2023-01-01)

Agomelatine Attenuates Isoflurane-Induced Inflammation and Damage in Brain Endothelial Cells
by: Cheng F, et al.
Published: (2020-12-01)

Optimization and improvement of the synthesis method of agomelatine
by: Lei LIU, et al.
Published: (2018-02-01)

Placebo Effect in the Treatment of Depression and Anxiety
by: Irving Kirsch
Published: (2019-06-01)

Impact of Mental Health Treatment on Outcomes in Patients With Heart Failure and Ischemic Heart Disease
by: Cheryl N. Carmin, et al.
Published: (2024-04-01)

ANXIETY AND DEPRESSION IN INTERNAL MEDICINE
by: A. V. Fedotova
Published: (2016-01-01)